close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by OrsoBio, Inc.

News headline image
OrsoBio Announces Positive Topline Phase 1b/2a Clinical Data for its Oral Mitochondrial Protonophore TLC-6740 in Combination with Tirzepatide
From OrsoBio, Inc.
Via Business Wire
News headline image
OrsoBio to Present Clinical and Preclinical Data on Mitochondrial Protonophore Portfolio for Obesity at ObesityWeek® 2025
From OrsoBio, Inc.
Via Business Wire
News headline image
OrsoBio to Present Preclinical Data on Mitochondrial Protonophore Portfolio in Models of Obesity at the American Diabetes Association’s 85th Scientific Sessions
From OrsoBio, Inc.
Via Business Wire
News headline image
OrsoBio Announces Publication of Preclinical Data on Novel Approach for Regulating Metabolic Dysfunction and Reducing Inflammation and Fibrosis
From OrsoBio, Inc.
Via Business Wire
News headline image
OrsoBio Announces Oversubscribed $67 Million Series B Financing to Accelerate Mitochondrial Protonophore Portfolio Targeting Obesity and Associated Disorders
From OrsoBio, Inc.
Via Business Wire
News headline image
OrsoBio to Present Phase 1 and Preclinical Data for Liver-Targeted Mitochondrial Protonophore TLC-6740 at the American Diabetes Association’s 84th Scientific Sessions
From OrsoBio, Inc.
Via Business Wire
News headline image
OrsoBio Announces $60M Series A Financing to Advance Metabolic Portfolio for the Treatment of Obesity and Associated Disorders
From OrsoBio, Inc.
Via Business Wire
News headline image
OrsoBio to Present Phase 1 Data for the Liver-Targeted LXR Inverse Agonist TLC-2716 in Development for Severe Hypertriglyceridemia and NASH at AHA’s Scientific Sessions 2023
From OrsoBio, Inc.
Via Business Wire
News headline image
OrsoBio to Present Phase 1 Data for the Liver-Targeted Mitochondrial Protonophore TLC-6740 in Development for the Treatment of Obesity at ObesityWeek® 2023
From OrsoBio, Inc.
Via Business Wire
News headline image
OrsoBio Announces Phase 1 Trial of TLC-6740, a Mitochondrial Protonophore for the Treatment of Obesity and Associated Diseases
From OrsoBio, Inc.
Via Business Wire
News headline image
OrsoBio Announces First Patient Dosed in Phase 2 Clinical Trial of the ACC2 Inhibitor TLC-3595, a Potential Treatment for Type 2 Diabetes
From OrsoBio, Inc.
Via Business Wire
News headline image
OrsoBio Announces Presentation of Five Abstracts at AASLD’s The Liver Meeting® 2022 Highlighting Programs for Severe Metabolic Disorders
From OrsoBio, Inc.
Via Business Wire
News headline image
OrsoBio Acquires Phase 2-Ready, Selective ACC2 Inhibitor from Shionogi & Co., Ltd. for the Treatment of Type 2 Diabetes
From OrsoBio, Inc.
Via Business Wire
News headline image
OrsoBio Announces Acquisition of LXR Inverse Agonist Program for Treatment of Severe Dyslipidemias from Phenex Pharmaceuticals
From OrsoBio, Inc.
Via Business Wire
News headline image
OrsoBio Acquires ACMSD Inhibitor Program to Address Mitochondrial Dysfunction from Mitobridge, an Astellas Company
From OrsoBio, Inc.
Via Business Wire
News headline image
OrsoBio Announces Exclusive License to Intellectual Property Relating to Mitochondrial Protonophores for the Treatment of Severe Metabolic Disorders
From OrsoBio, Inc.
Via Business Wire
News headline image
OrsoBio Initiates IND-Enabling Activities for Liver-Targeted Mitochondrial Protonophore TLC-6740 for the Treatment of Severe Metabolic Disorders
From OrsoBio, Inc.
Via Business Wire
News headline image
OrsoBio Launches to Develop Novel Therapies for Patients with Severe Metabolic Disorders
From OrsoBio, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today